Steroid Injection Therapy for Peyronie’s Disease: A 10-Year Summary and Review of 38 Cases

Desanctis, Peter N.; Furey, Clement A.

doi:10.1016/s0022-5347(17)62993-8

Cited by 74 publications

(12 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dupuytren's contracture was found in 15.4%. Whilst this is a similar incidence to that previously reported (Gallizia, 1964)' it is a considerably higher proportion than the 2 to 3% expected in the general population (Desanctis and Furey, 1967). There is evidence that Dupuytren's contracture may be inherited as a dominant gene and manifest itself in middle age (Ling, 1963).…”

Section: Discussionsupporting

confidence: 84%

Factors Associated in the Aetiology of Peyronie's Disease

Chilton

Castle

Westwood

et al. 1982

British Journal of Urology

View full text Add to dashboard Cite

In a retrospective study of 408 patients with Peyronie's disease 8 (1.9%) patients gave a positive family history for the condition. Sixty-three (15.4%) patients had a Dupuytren's contracture and trauma was considered to be an aetiological factor in 88 (21.5%) patients. One hundred and twenty-two (29.9%) patients had evidence of atherosclerosis and this is thought to be a factor in the pathogenesis of the disease. Peyronie's disease is not a single disease entity and is associated with many aetiological factors.

show abstract

Section: Discussionsupporting

confidence: 84%

Factors Associated in the Aetiology of Peyronie's Disease

Chilton

Castle

Westwood

et al. 1982

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Although six studies using injectable corticosteroids for the treatment of PD showed positive outcomes from treatment, the authors believe that the therapeutic effects were because of the mechanical effects of the injection and not to the drug action itself [125][126][127][128][129][130][131].…”

Section: Intralesional Injections Steroidsmentioning

confidence: 99%

The Management of Peyronie’s Disease: Evidence-based 2010 Guidelines

Ralph,

Gonzalez-Cadavid,

Mirone

et al. 2010

The Journal of Sexual Medicine

315

437

View full text Add to dashboard Cite

Introduction The field of Peyronie’s disease is evolving and there is need for a state-of-the-art information in this area. Aim To develop an evidence-based state-of-the-art consensus report on the management of Peyronie’s disease. Methods To provide state-of-the-art knowledge regarding the prevalence, etiology, medical and surgical management of Peyronie’s Disease, representing the opinion of leading experts developed in a consensus process over a 2-year period. Main Outcome Measures Expert opinion was based on grading of evidence-based medical literature, widespread internal committee discussion, public presentation, and debate. Conclusions The real etiology of Peyronie’s disease and the mechanisms of formation of the plaque still remain obscure. Although conservative management is obtaining a progressively larger consensus among the experts, surgical correction still remains the mainstay treatment for this condition.

show abstract

“…50 The risks associated with steroid use, (wound infection, local bruising/bleeding) coupled with limited efficacy do not support its use. 51 Hyaluronic acid and botulinum toxin A (onabotulinumtoxinA) Hyaluronic acid (HA) is a glycosaminoglycan that has been shown to regulate the immune system by decreasing inflammatory cytokines, and thus has been used to reduce inflammation and scar formation. Two retrospective studies and a more recent prospective study have shown a reduction in penile plaque size and curvature, as well as improved penile rigidity.…”

Section: Corticosteroidsmentioning

confidence: 99%

2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature

Bella

Lee

Grober

et al. 2018

CUAJ

View full text Add to dashboard Cite

Peyronie’s disease (PD) is a highly prevalent condition that affects the physical and psychosocial well-being and quality of life (QoL) for thousands of Canadian men. The specific etiology of PD remains poorly understood and there remains a paucity of randomized placebo-controlled trials evaluating treatment interventions.1-3 PD can be found in up to 8.9% of men, a remarkable increase in cited prevalence that is attributable to growing awareness (as historical data suggested a rate of less than 1%); the burden of disease is significant, and PD is often present in otherwise healthy men. The following guidelines were crafted by the committee with a full awareness of the limitations of the literature, and sought to provide actionable recommendations to guide PD care in the Canadian health system.

show abstract

Steroid Injection Therapy for Peyronie’s Disease: A 10-Year Summary and Review of 38 Cases

Cited by 74 publications

References 2 publications

Factors Associated in the Aetiology of Peyronie's Disease

Factors Associated in the Aetiology of Peyronie's Disease

The Management of Peyronie’s Disease: Evidence-based 2010 Guidelines

2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature

Contact Info

Product

Resources

About